{"schema":"sb.node.v1","id":"sb:e/c5643341102ee43328b615e6","kind":"entity","label":{"text":"drug safety","locale":"en"},"identity":{"anchor":"label:en:drug safety","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T19:01:08.010113+00:00","snapshot":"deploy 80531d169c8eb96bdf7c17cfba4475a3073c6ff3"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":65,"separatePublishers":19,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-08","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.292: about 71% of mentions carry no typed assertion"]}},"dimensions":{"domains":["south_korea","biotech_pharma","pharma-regulatory"],"activeDays":35,"assertions":{"regulatory-approval":14,"meeting-visit":2,"sports-outcome":1,"election":1,"ipo-listing":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/e046f7022f1260d716d83389","kind":"observation","label":"Fierce Biotech · 2026-10-07 · New Approach Methodologies for Drug Safety Testing: Research to Clinical Development","url":"https://www.fiercebiotech.com/resource/new-approach-methodologies-drug-safety-testing-research-clinical-development"},{"id":"sb:o/4976100ebecd7b60076e092c","kind":"observation","label":"BIOENGINEER.ORG · 2026-10-05 · Human Organs on Chips Recreate Body’s Niches to Predict Drug Safety","url":"https://bioengineer.org/human-organs-on-chips-recreate-bodys-niches-to-predict-drug-safety/"},{"id":"sb:o/173e56f8a0de845f53721d73","kind":"observation","label":"FDA · 2026-10-01 · Drug Safety-related Labeling Changes (SrLC) Database Overview: Updates to Safety Information in FDA-Approved Prescription Drug Labeling","url":"http://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-related-labeling-changes-srlc-database-overview-updates-safety-information-fda-approved"},{"id":"sb:o/80e038426da4aea2fb3f84a5","kind":"observation","label":"FDA · 2026-10-01 · Drug Safety Information","url":"http://www.fda.gov/drugs/information-health-care-professionals-drugs/drug-safety-information"},{"id":"sb:o/a7e3ba0895496004b91bfc42","kind":"observation","label":"FDA Drug News · 2026-09-18 · Drug Safety Oversight Board (DSB) Meeting June 26, 2024","url":"http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-safety-oversight-board-dsb-meeting-june-26-2024"},{"id":"sb:o/dc6ac65edaa9504e72849036","kind":"observation","label":"FDA · 2026-09-16 · Drug Safety Communications","url":"http://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications"},{"id":"sb:o/519bfdd631cd9de60a9b7d49","kind":"observation","label":"FDA Drug News · 2026-06-10 · Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequ…","url":"http://www.fda.gov/drugs/investigational-new-drug-ind-application/final-rule-investigational-new-drug-safety-reporting-requirements-human-drug-and-biological-products"},{"id":"sb:o/cdcebffbfa34eabcde7ffb2e","kind":"observation","label":"FDA Drug News · 2026-06-09 · Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death","url":"http://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk"},{"id":"sb:o/92e47bf8a2118c225bc3e33a","kind":"observation","label":"FDA Drug News · 2026-05-28 · Drug Safety and Availability","url":"http://www.fda.gov/drugs/drug-safety-and-availability"},{"id":"sb:o/72b06b01ab5b5728ae54e52b","kind":"observation","label":"FDA Drug News · 2026-05-21 · FDA Drug Safety Podcasts","url":"http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-podcasts"}],"cursor":"c1.eyJpZCI6InNiOmUvYzU2NDMzNDExMDJlZTQzMzI4YjYxNWU2IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDE5OjAxOjA4LjAxMDExMyswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/86fd90b1b57f5648627fb6c5"},{"kind":"relation","label":"co-mentioned with south korea (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3751e4831282a609fc1403d5"},{"kind":"relation","label":"co-mentioned with drug administration (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/000c9f476171c4128e9d9b6b"},{"kind":"relation","label":"co-mentioned with drug development (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/24f47b5ad6d3d79696fd3a9a"},{"kind":"relation","label":"co-mentioned with ai (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ad7d29b2d1bea82608127a31"},{"kind":"relation","label":"co-mentioned with studie (17 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f17159ee7dd906c0824d4c9b"},{"kind":"relation","label":"co-mentioned with united states (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2940d2a3f6bc106df7a31c8c"},{"kind":"relation","label":"co-mentioned with seoul (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/02fa0c6d1d47401842b3c556"},{"kind":"relation","label":"co-mentioned with cder (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/097af3b4b8da948dac7599e1"},{"kind":"relation","label":"co-mentioned with u.s. food (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/03eb74869bbcf5fb8ad3a84b"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/c5643341102ee43328b615e6","mcp":"traverse {\"id\":\"sb:e/c5643341102ee43328b615e6\"}","page":"/entity/drug-safety/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c5643341102ee43328b615e6\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c5643341102ee43328b615e6\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c5643341102ee43328b615e6\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/c5643341102ee43328b615e6\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}